Which has higher earnings and valuation, ABVX or IRON?

Abivax is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Disc Medicine N/A N/A -$212.18M -$6.62 N/A

Is ABVX or IRON more profitable?

Disc Medicine's return on equity of -36.94% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Disc Medicine N/A -36.94% -33.88%

Does the media refer more to ABVX or IRON?

In the previous week, Abivax had 3 more articles in the media than Disc Medicine. MarketBeat recorded 9 mentions for Abivax and 6 mentions for Disc Medicine. Abivax's average media sentiment score of 1.63 beat Disc Medicine's score of 0.53 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Disc Medicine 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer IRON or RDY?

Disc Medicine currently has a consensus price target of $104.44, suggesting a potential upside of 40.91%. Given Disc Medicine's stronger consensus rating and higher possible upside, research analysts clearly believe Disc Medicine is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Disc Medicine 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73 Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media prefer IRON or RDY?

In the previous week, Dr. Reddy's Laboratories had 8 more articles in the media than Disc Medicine. MarketBeat recorded 14 mentions for Dr. Reddy's Laboratories and 6 mentions for Disc Medicine. Disc Medicine's average media sentiment score of 0.53 beat Dr. Reddy's Laboratories' score of -0.23 indicating that Disc Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer IRON or CYTK?

In the previous week, Cytokinetics had 4 more articles in the media than Disc Medicine. MarketBeat recorded 10 mentions for Cytokinetics and 6 mentions for Disc Medicine. Cytokinetics' average media sentiment score of 1.17 beat Disc Medicine's score of 0.53 indicating that Cytokinetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ARWR or IRON?

In the previous week, Arrowhead Pharmaceuticals had 34 more articles in the media than Disc Medicine. MarketBeat recorded 40 mentions for Arrowhead Pharmaceuticals and 6 mentions for Disc Medicine. Arrowhead Pharmaceuticals' average media sentiment score of 0.96 beat Disc Medicine's score of 0.53 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 21 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Disc Medicine 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IRON or KRYS?

In the previous week, Krystal Biotech had 5 more articles in the media than Disc Medicine. MarketBeat recorded 11 mentions for Krystal Biotech and 6 mentions for Disc Medicine. Krystal Biotech's average media sentiment score of 1.52 beat Disc Medicine's score of 0.53 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Disc Medicine (IRON) Competitors

$74.12 -1.74 (-2.29%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$74.10 -0.03 (-0.03%)

As of 07/24/2026 07:34 PM Eastern

Compare

IRON vs. ABVX, RDY, CYTK, ARWR, and KRYS

Should you buy Disc Medicine stock or one of its competitors? MarketBeat compares Disc Medicine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Disc Medicine include Abivax (ABVX), Dr. Reddy's Laboratories (RDY), Cytokinetics (CYTK), Arrowhead Pharmaceuticals (ARWR), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry.

How does Disc Medicine compare to Abivax?

Abivax (NASDAQ:ABVX) and Disc Medicine (NASDAQ:IRON) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Abivax has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

In the previous week, Abivax had 3 more articles in the media than Disc Medicine. MarketBeat recorded 9 mentions for Abivax and 6 mentions for Disc Medicine. Abivax's average media sentiment score of 1.63 beat Disc Medicine's score of 0.53 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Disc Medicine	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.9% of Abivax shares are owned by institutional investors. Comparatively, 83.7% of Disc Medicine shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Abivax is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A

Disc Medicine's return on equity of -36.94% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Disc Medicine	N/A	-36.94%	-33.88%

Abivax currently has a consensus price target of $156.50, indicating a potential upside of 24.50%. Disc Medicine has a consensus price target of $104.44, indicating a potential upside of 40.91%. Given Disc Medicine's higher possible upside, analysts clearly believe Disc Medicine is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Disc Medicine beats Abivax on 8 of the 13 factors compared between the two stocks.

How does Disc Medicine compare to Dr. Reddy's Laboratories?

Disc Medicine (NASDAQ:IRON) and Dr. Reddy's Laboratories (NYSE:RDY) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

Disc Medicine has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market.

Dr. Reddy's Laboratories has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A
Dr. Reddy's Laboratories	$3.58B	2.75	$456M	$0.58	20.30

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Disc Medicine's net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 9.49% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-36.94%	-33.88%
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

Disc Medicine currently has a consensus price target of $104.44, suggesting a potential upside of 40.91%. Given Disc Medicine's stronger consensus rating and higher possible upside, research analysts clearly believe Disc Medicine is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Dr. Reddy's Laboratories had 8 more articles in the media than Disc Medicine. MarketBeat recorded 14 mentions for Dr. Reddy's Laboratories and 6 mentions for Disc Medicine. Disc Medicine's average media sentiment score of 0.53 beat Dr. Reddy's Laboratories' score of -0.23 indicating that Disc Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Dr. Reddy's Laboratories beats Disc Medicine on 8 of the 15 factors compared between the two stocks.

How does Disc Medicine compare to Cytokinetics?

Disc Medicine (NASDAQ:IRON) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

In the previous week, Cytokinetics had 4 more articles in the media than Disc Medicine. MarketBeat recorded 10 mentions for Cytokinetics and 6 mentions for Disc Medicine. Cytokinetics' average media sentiment score of 1.17 beat Disc Medicine's score of 0.53 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Disc Medicine has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market.

Disc Medicine has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-36.94%	-33.88%
Cytokinetics	-784.02%	N/A	-52.86%

Disc Medicine currently has a consensus price target of $104.44, indicating a potential upside of 40.91%. Cytokinetics has a consensus price target of $99.90, indicating a potential upside of 23.73%. Given Disc Medicine's higher possible upside, analysts plainly believe Disc Medicine is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Cytokinetics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91

83.7% of Disc Medicine shares are held by institutional investors. 3.8% of Disc Medicine shares are held by insiders. Comparatively, 2.6% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Disc Medicine has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A
Cytokinetics	$105.82M	94.95	-$784.96M	-$6.84	N/A

Summary

Disc Medicine beats Cytokinetics on 9 of the 16 factors compared between the two stocks.

How does Disc Medicine compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Disc Medicine (NASDAQ:IRON) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Disc Medicine has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Disc Medicine's return on equity of -36.94% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Disc Medicine	N/A	-36.94%	-33.88%

Arrowhead Pharmaceuticals has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.7% of Disc Medicine shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 3.8% of Disc Medicine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Arrowhead Pharmaceuticals has higher revenue and earnings than Disc Medicine. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.54	-$1.63M	-$2.15	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A

In the previous week, Arrowhead Pharmaceuticals had 34 more articles in the media than Disc Medicine. MarketBeat recorded 40 mentions for Arrowhead Pharmaceuticals and 6 mentions for Disc Medicine. Arrowhead Pharmaceuticals' average media sentiment score of 0.96 beat Disc Medicine's score of 0.53 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	21 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Disc Medicine	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arrowhead Pharmaceuticals presently has a consensus target price of $93.83, suggesting a potential upside of 9.62%. Disc Medicine has a consensus target price of $104.44, suggesting a potential upside of 40.91%. Given Disc Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Disc Medicine is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Arrowhead Pharmaceuticals beats Disc Medicine on 8 of the 15 factors compared between the two stocks.

How does Disc Medicine compare to Krystal Biotech?

Disc Medicine (NASDAQ:IRON) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

Krystal Biotech has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A
Krystal Biotech	$389.13M	25.39	$204.83M	$7.48	44.81

Disc Medicine presently has a consensus price target of $104.44, indicating a potential upside of 40.91%. Krystal Biotech has a consensus price target of $360.67, indicating a potential upside of 7.60%. Given Disc Medicine's higher probable upside, equities analysts clearly believe Disc Medicine is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

Krystal Biotech has a net margin of 53.92% compared to Disc Medicine's net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-36.94%	-33.88%
Krystal Biotech	53.92%	19.25%	17.62%

83.7% of Disc Medicine shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 3.8% of Disc Medicine shares are held by insiders. Comparatively, 13.1% of Krystal Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Disc Medicine has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market.

In the previous week, Krystal Biotech had 5 more articles in the media than Disc Medicine. MarketBeat recorded 11 mentions for Krystal Biotech and 6 mentions for Disc Medicine. Krystal Biotech's average media sentiment score of 1.52 beat Disc Medicine's score of 0.53 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Krystal Biotech beats Disc Medicine on 13 of the 15 factors compared between the two stocks.

Get Disc Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRON vs. The Competition

Export

Metric	Disc Medicine	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.89B	$3.67B	$6.88B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-11.20	21.11	27.00	23.71
Price / Sales	N/A	165.33	492.77	76.09
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	3.80	7.88	10.28	6.07
Net Income	-$212.18M	$23.81M	$3.60B	$331.84M
7 Day Performance	-2.67%	-3.79%	-1.25%	-1.53%
1 Month Performance	5.64%	-2.59%	-0.35%	-2.46%
1 Year Performance	22.29%	32.85%	18.41%	13.66%

Disc Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRON Disc Medicine	2.0557 of 5 stars	$74.12 -2.3%	$104.44 +40.9%	+22.4%	$2.89B	N/A	N/A	30
ABVX Abivax	4.0166 of 5 stars	$134.91 -0.8%	$148.54 +10.1%	+80.2%	$10.76B	N/A	N/A	61	Positive News Analyst Forecast
RDY Dr. Reddy's Laboratories	2.0403 of 5 stars	$12.85 -0.6%	N/A	-19.9%	$10.72B	$3.58B	22.15	27,527	News Coverage Earnings Report Analyst Downgrade
CYTK Cytokinetics	3.5123 of 5 stars	$81.93 -0.4%	$99.90 +21.9%	+116.4%	$10.19B	$88.04M	N/A	250	News Coverage Positive News
ARWR Arrowhead Pharmaceuticals	1.9116 of 5 stars	$71.91 -3.0%	$88.17 +22.6%	+426.4%	$10.13B	$829.45M	N/A	400	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRON) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Disc Medicine (IRON) Competitors

IRON vs. ABVX, RDY, CYTK, ARWR, and KRYS

How does Disc Medicine compare to Abivax?

Summary

How does Disc Medicine compare to Dr. Reddy's Laboratories?

Summary

How does Disc Medicine compare to Cytokinetics?

Summary

How does Disc Medicine compare to Arrowhead Pharmaceuticals?

Summary

How does Disc Medicine compare to Krystal Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRON vs. The Competition

Disc Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Disc Medicine (IRON) Competitors

IRON vs. ABVX, RDY, CYTK, ARWR, and KRYS

How does Disc Medicine compare to Abivax?

Which has more risk and volatility, ABVX or IRON?

Does the media refer more to ABVX or IRON?

Do institutionals & insiders believe in ABVX or IRON?

Which has higher earnings and valuation, ABVX or IRON?

Is ABVX or IRON more profitable?

Do analysts prefer ABVX or IRON?

Summary

How does Disc Medicine compare to Dr. Reddy's Laboratories?

Which has more volatility and risk, IRON or RDY?

Which has better earnings and valuation, IRON or RDY?

Do institutionals and insiders hold more shares of IRON or RDY?

Is IRON or RDY more profitable?

Do analysts prefer IRON or RDY?

Does the media prefer IRON or RDY?

Summary

How does Disc Medicine compare to Cytokinetics?

Does the media prefer IRON or CYTK?

Which has more risk & volatility, IRON or CYTK?

Is IRON or CYTK more profitable?

Do analysts prefer IRON or CYTK?

Do insiders and institutionals believe in IRON or CYTK?

Which has higher valuation & earnings, IRON or CYTK?

Summary

How does Disc Medicine compare to Arrowhead Pharmaceuticals?

Is ARWR or IRON more profitable?

Which has more volatility and risk, ARWR or IRON?

Do institutionals & insiders have more ownership in ARWR or IRON?

Which has stronger earnings & valuation, ARWR or IRON?

Does the media favor ARWR or IRON?

Do analysts rate ARWR or IRON?

Summary

How does Disc Medicine compare to Krystal Biotech?

Which has preferable valuation & earnings, IRON or KRYS?

Do analysts recommend IRON or KRYS?

Is IRON or KRYS more profitable?

Do institutionals and insiders believe in IRON or KRYS?

Which has more volatility & risk, IRON or KRYS?

Does the media prefer IRON or KRYS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRON vs. The Competition

Disc Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools